Cancer Stem Cells Use “Normal” Genes in Abnormal Ways

University of Colorado Cancer Center study shows that "normal" gene CDK1 interacts with "abnormal" gene Sox2 to keep cancer stem cells "stemmy."
12-Oct-2018 8:05 AM EDT Add to Favorites

Cancer Hijacks the Microbiome to Glut Itself on Glucose

A University of Colorado Cancer Center study published today in the journal Cancer Cell shows that leukemia undercuts the ability of normal cells to consume glucose, thus leaving more glucose available to feed its own growth.
28-Sep-2018 11:05 AM EDT Add to Favorites

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

Results of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.
25-Sep-2018 8:05 AM EDT Add to Favorites

Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer (NSCLC) presented on the press program of the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on...
24-Sep-2018 8:45 AM EDT Add to Favorites

New Combination Treatment Targets Pre-Leukemia Stem Cells

Omacetaxine (to block protein synthesis) with venetoclax (to block oxidative phosphorylation), was highly effective against CD123+ leukemia stem cells.
12-Sep-2018 1:05 PM EDT Add to Favorites

Like Shark Attack and the Lottery, Unconscious Bias Influences Cancer Screening

Doctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
17-Aug-2018 12:15 PM EDT Add to Favorites

No single test identifies all ROS1+ lung cancer patients

University of Colorado Cancer Center study shows that common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.
8-Aug-2018 11:05 AM EDT Add to Favorites

Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia

Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML.
30-Jul-2018 10:05 AM EDT Add to Favorites

see all news